{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:46:52Z","timestamp":1782604012911,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1106,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41379-019-0345-2","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T13:02:31Z","timestamp":1565010151000},"page":"138-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases"],"prefix":"10.1016","volume":"33","author":[{"given":"Ying","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Yu","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horace H.Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin-Long","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hing-Wai","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine T.Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah","family":"Cheuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W.K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.F.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K.L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hextan Y.S.","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie N.Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-9838","authenticated-orcid":false,"given":"Philip P.C.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-019-0345-2_bib1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1285::AID-CNCR25>3.0.CO;2-P","article-title":"Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival","volume":"86","author":"Ragnarsson-Olding","year":"1999","journal-title":"Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.AOG.0000271209.67461.91","article-title":"Vulvar melanoma: a multivariable analysis of 644 patients","volume":"110","author":"Sugiyama","year":"2007","journal-title":"Obstet Gynecol."},{"key":"10.1038\/s41379-019-0345-2_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0002-9378(94)90137-6","article-title":"Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival","volume":"171","author":"Weinstock","year":"1994","journal-title":"Am J obstet Gynecol."},{"key":"10.1038\/s41379-019-0345-2_bib4","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/IGC.0000000000000198","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas","volume":"24","author":"Leitao","year":"2014","journal-title":"Int J Gynecol Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PGP.0000000000000480","article-title":"Primary cervical malignant melanoma: 2 cases and a literature review","volume":"38","author":"Yin","year":"2019","journal-title":"Int J Gynecol Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2018.04.562","article-title":"Melanoma of the lower genital tract: Prognostic factors and treatment modalities","volume":"150","author":"Gadducci","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0345-2_bib7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/00000478-200211000-00007","article-title":"Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases","volume":"26","author":"Gupta","year":"2002","journal-title":"Am J Surg Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/00313029109063595","article-title":"Malignant melanoma of the female genital tract: a report of nine cases in the Chinese of Hong Kong","volume":"23","author":"Khoo","year":"1991","journal-title":"Pathology."},{"key":"10.1038\/s41379-019-0345-2_bib9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/IGC.0b013e3182980ffb","article-title":"Vulvar\/vaginal melanoma: an updated surveillance epidemiology and end results database review, comparison with cutaneous melanoma and significance of racial disparities","volume":"23","author":"Mert","year":"2013","journal-title":"Int J Gynecol Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2011.11.921","article-title":"Clinicopathologic study of 85 cases of melanoma of the female genitalia","volume":"67","author":"Tcheung","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"10.1038\/s41379-019-0345-2_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2217\/fon.12.179","article-title":"Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations","volume":"9","author":"Bradish","year":"2013","journal-title":"Future Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib12","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat Rev Dis Prim."},{"key":"10.1038\/s41379-019-0345-2_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"10.1038\/s41379-019-0345-2_bib14","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med."},{"key":"10.1038\/s41379-019-0345-2_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"10.1038\/s41379-019-0345-2_bib16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/PGP.0000000000000454","article-title":"Frequent PD-L1 Expression in Malignant Melanomas of the Vulva","volume":"37","author":"Saleh","year":"2018","journal-title":"Int J Gynecol Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib19","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest."},{"key":"10.1038\/s41379-019-0345-2_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.humpath.2017.12.022","article-title":"Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas","volume":"73","author":"Ch\u0142opik","year":"2018","journal-title":"Hum Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib21","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti\u2010PD\u20101 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1309\/AJCPCX2D9YULBBLG","article-title":"High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma","volume":"142","author":"Alvino","year":"2014","journal-title":"Am J Clin Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CMR.0000000000000449","article-title":"Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes","volume":"28","author":"Lee","year":"2018","journal-title":"Melanoma Res."},{"key":"10.1038\/s41379-019-0345-2_bib24","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T cell infiltrates in metastatic melanoma samples from variable anatomic sites","volume":"12","author":"Kluger","year":"2015","journal-title":"Clin Cancer Res."},{"key":"10.1038\/s41379-019-0345-2_bib25","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1038\/s41379-019-0345-2_bib26","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res."},{"key":"10.1038\/s41379-019-0345-2_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science."},{"key":"10.1038\/s41379-019-0345-2_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CMR.0000000000000298","article-title":"Microsatellite instability in melanoma: a comprehensive review","volume":"26","author":"Kube\u010dek","year":"2016","journal-title":"Melanoma Res."},{"key":"10.1038\/s41379-019-0345-2_bib29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/gcc.20567","article-title":"Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma","volume":"47","author":"Castiglia","year":"2008","journal-title":"Genes Chromosomes Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00008390-200304000-00009","article-title":"Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases","volume":"13","author":"Palmieri","year":"2003","journal-title":"Melanoma Res."},{"key":"10.1038\/s41379-019-0345-2_bib31","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene."},{"key":"10.1038\/s41379-019-0345-2_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2014.04.056","article-title":"NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract\u2014a study of 24 cases from the Netherlands","volume":"134","author":"van Engen-van Grunsven","year":"2014","journal-title":"Gynecol Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaad.2014.03.033","article-title":"Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract","volume":"71","author":"Tseng","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"10.1038\/s41379-019-0345-2_bib34","first-page":"7043","article-title":"BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival","volume":"37","author":"Ponti","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1038\/s41379-019-0345-2_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"Long","year":"2013","journal-title":"Am J Surg Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jcp.2004.022509","article-title":"BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs","volume":"58","author":"Wong","year":"2005","journal-title":"J Clin Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib37","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.2013.211","article-title":"Comparison of molecular abnormalities in vulvar and vaginal melanomas","volume":"27","author":"Aulmann","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0345-2_bib38","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1245\/s10434-014-4215-3","article-title":"Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases","volume":"22","author":"Seifried","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/s41379-019-0345-2_bib39","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(08)70254-7","article-title":"Management of primary melanoma of the female urogenital tract","volume":"9","author":"Piura","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12253-011-9363-1","article-title":"B-Raf mutations, microsatellite instability and p53 protein expression in sporadic basal cell carcinomas","volume":"17","author":"Stamatelli","year":"2011","journal-title":"Pathol Oncol Res."},{"key":"10.1038\/s41379-019-0345-2_bib41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/CMR.0b013e32835e590e","article-title":"A large retrospective multicenter study of vaginal melanomas: implications for new management","volume":"23","author":"Vaysse","year":"2013","journal-title":"Melanoma Res."},{"key":"10.1038\/s41379-019-0345-2_bib42","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/CMR.0000000000000075","article-title":"Extracutaneous melanoma epidemiology in British Columbia","volume":"24","author":"Haiducu","year":"2014","journal-title":"Melanoma Res."},{"key":"10.1038\/s41379-019-0345-2_bib43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/dc.20917","article-title":"Metastatic malignant melanoma of the uterine cervix: First diagnosed on liquid\u2010based cytology","volume":"36","author":"\u00dcz\u00fcm","year":"2008","journal-title":"Diagn Cytopathol."},{"key":"10.1038\/s41379-019-0345-2_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/dc.2014","article-title":"Primary malignant melanoma of the uterine cervix: report of a case diagnosed by cervical scrape cytology and review of the literature","volume":"25","author":"Deshpande","year":"2001","journal-title":"Diagn Cytopathol."},{"key":"10.1038\/s41379-019-0345-2_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5468\/ogs.2016.59.5.415","article-title":"Primary malignant melanoma of cervix and vagina","volume":"59","author":"Lee","year":"2016","journal-title":"Obstet Gynecol Sci."},{"key":"10.1038\/s41379-019-0345-2_bib46","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/AOG.0b013e3181fb8045","article-title":"Primary malignant melanoma of the vagina","volume":"116","author":"Frumovitz","year":"2010","journal-title":"Obstet Gynecol."},{"key":"10.1038\/s41379-019-0345-2_bib47","first-page":"295","article-title":"Malignant melanoma of the vagina. A report of 15 cases","volume":"21","author":"Cobellis","year":"2000","journal-title":"Eur J Gynaecol Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2017.08.023","article-title":"Gynecologic melanomas: A clinicopathologic and molecular analysis","volume":"147","author":"Udager","year":"2017","journal-title":"Gynecol Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib49","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/LGT.0000000000000204","article-title":"Surgical management and prognostic factors of vulvovaginal melanoma","volume":"20","author":"Ditto","year":"2016","journal-title":"J Low Genit Trac Dis."},{"key":"10.1038\/s41379-019-0345-2_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/BF02524343","article-title":"Primary vaginal melanoma: a critical analysis of therapy","volume":"11","author":"Miner","year":"2004","journal-title":"Ann Surg Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib51","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2012.06.013","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline\u2013Update 2012","volume":"48","author":"Garbe","year":"2012","journal-title":"Eur J Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib52","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IGC.0000000000001018","article-title":"Treatment of genital melanoma: are we ready for innovative therapies?","volume":"27","author":"Ditto","year":"2017","journal-title":"Int J Gynecol Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib53","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1245\/s10434-012-2475-3","article-title":"Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline","volume":"19","author":"Wong","year":"2012","journal-title":"Ann Surg Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ygyno.2013.02.028","article-title":"Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy","volume":"129","author":"Janco","year":"2013","journal-title":"Gynecol Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00008390-200412000-00012","article-title":"Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma","volume":"14","author":"Harting","year":"2004","journal-title":"Melanoma Res."},{"key":"10.1038\/s41379-019-0345-2_bib56","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview","volume":"19","author":"Serrone","year":"2000","journal-title":"J Exp Clin Cancer Res."},{"key":"10.1038\/s41379-019-0345-2_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10147-017-1193-z","article-title":"Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer","volume":"23","author":"Saito","year":"2018","journal-title":"Int J Clin Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gore.2016.04.001","article-title":"Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract","volume":"16","author":"Schiavone","year":"2016","journal-title":"Gynecol Oncol Rep."},{"key":"10.1038\/s41379-019-0345-2_bib59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in Cancer Treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1038\/s41379-019-0345-2_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol."},{"key":"10.1038\/s41379-019-0345-2_bib61","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti\u2013programmed death 1 antibody Pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib62","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death\u20101 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer."},{"key":"10.1038\/s41379-019-0345-2_bib63","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther."},{"key":"10.1038\/s41379-019-0345-2_bib64","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41379-018-0053-3","article-title":"Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma","volume":"31","author":"Chan","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0345-2_bib65","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","article-title":"PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison","volume":"23","author":"Sunshine","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1038\/s41379-019-0345-2_bib66","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/arpa.2015-0522-SA","article-title":"Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch Pathol Lab Med."},{"key":"10.1038\/s41379-019-0345-2_bib67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib68","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-019-0345-2_bib69","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1038\/s41379-019-0345-2_bib70","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1038\/s41379-019-0345-2_bib71","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/jdv.14486","article-title":"Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?","volume":"32","author":"Quereux","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1038\/s41379-019-0345-2_bib72","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1158\/0008-5472.CAN-11-1316","article-title":"Prognostic and predictive impact of intra-and peritumoral immune infiltrates","volume":"71","author":"Fridman","year":"2011","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-019-0345-2_bib73","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-019-0345-2_bib74","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/PAS.0000000000000848","article-title":"A novel numerical scoring system for melanoma tumor-infiltrating lymphocytes has better prognostic value than standard scoring","volume":"41","author":"Saldanha","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-019-0345-2_bib75","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-018-2485-z","article-title":"Precision immunoprofiling by image analysis and artificial intelligence","volume":"474","author":"Koelzer","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1038\/s41379-019-0345-2_bib76","doi-asserted-by":"crossref","first-page":"111110","DOI":"10.18632\/oncotarget.22624","article-title":"Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget."},{"key":"10.1038\/s41379-019-0345-2_bib77","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41379-019-0345-2_bib78","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/15384047.2016.1156263","article-title":"p.(L576P)-KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?","volume":"17","author":"Noujaim","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1038\/s41379-019-0345-2_bib79","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1349-7006.2008.00727.x","article-title":"Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib\u2010resistant gastrointestinal stromal tumor","volume":"99","author":"Nishida","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1038\/s41379-019-0345-2_bib80","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1535-7163.MCT-06-0641","article-title":"Resistance to c-KIT kinase inhibitors conferred by V654A mutation","volume":"6","author":"Roberts","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/s41379-019-0345-2_bib81","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2147\/OTT.S81558","article-title":"Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)","volume":"8","author":"Spitaleri","year":"2015","journal-title":"OncoTargets Ther"},{"key":"10.1038\/s41379-019-0345-2_bib82","doi-asserted-by":"crossref","first-page":"13399","DOI":"10.1074\/jbc.274.19.13399","article-title":"Inhibition of spontaneous receptor phosphorylation by residues in a putative \u03b1-helix in the KIT intracellular juxtamembrane region","volume":"274","author":"Ma","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1038\/s41379-019-0345-2_bib83","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1038\/s41379-019-0345-2_bib84","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/PAS.0b013e3181ef7431","article-title":"Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size","volume":"34","author":"Rossi","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib85","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat Genet."},{"key":"10.1038\/s41379-019-0345-2_bib86","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":"Large scale analysis of KIT aberrations in Chinese patients with melanoma","volume":"17","author":"Kong","year":"2011","journal-title":"Clin Cancer Res."},{"key":"10.1038\/s41379-019-0345-2_bib87","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0345-2_bib88","doi-asserted-by":"crossref","first-page":"303791","DOI":"10.1155\/2015\/303791","article-title":"Low mutational burden of eight genes involved in the MAPK\/ERK, PI3K\/AKT, and GNAQ\/11 pathways in female genital tract primary melanomas","volume":"2015","author":"Pappa","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1038\/s41379-019-0345-2_bib89","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/exd.13472","article-title":"BRAF mutations might be more common than supposed in vulvar melanomas","volume":"27","author":"Wylomanski","year":"2018","journal-title":"Exp Dermatol."},{"key":"10.1038\/s41379-019-0345-2_bib90","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jss.2016.04.029","article-title":"Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature","volume":"203","author":"Anwar","year":"2016","journal-title":"J Surg Res"},{"key":"10.1038\/s41379-019-0345-2_bib91","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/cup.12364","article-title":"Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma","volume":"41","author":"Pearlstein","year":"2014","journal-title":"J Cutan Pathol."},{"key":"10.1038\/s41379-019-0345-2_bib92","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jim-2016-000342","article-title":"Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge","volume":"65","author":"Naboush","year":"2017","journal-title":"J Invest Med."},{"key":"10.1038\/s41379-019-0345-2_bib93","first-page":"341","article-title":"Microsatellite instability predicts response to anti-PD1 immunotherapy in metastatic melanoma","volume":"26","author":"Roncati","year":"2018","journal-title":"Acta Derm Croat."}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0345-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522200953X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522200953X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:42:29Z","timestamp":1760229749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089339522200953X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S089339522200953X"],"URL":"https:\/\/doi.org\/10.1038\/s41379-019-0345-2","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-019-0345-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}